


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on August 31, 2010.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 CFR 1.322  
AND UNDER 37 CFR 1.323  
Docket No. ARS.124

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson  
Issued : June 22, 2010  
Patent No. : 7,740,833  
Conf. No. : 9024  
For : Therapeutic Uses of Chemokine Variants

Mail Stop Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR 1.322 (OFFICE MISTAKE) AND  
UNDER 37 CFR 1.323 (APPLICANT MISTAKE)

Sir:

A Certificate of Correction for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

Patent Reads:

Column 2, line 13:

“relate d to”

Column 2, line 18:

“even though has been”

Application Should Read:

Page 2, line 25:

--related to--

Page 3, line 4:

--even though it has been--

Column 5, line 45:

“results altered”

Page 9, line 24:

--results are altered--

Column 10, line 17:

“derived form”

Page 18, line 24:

--derived from--

Column 13, lines 10-12:

“fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl-ethyl”

Page 24, lines 15-17:

--fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl--

Column 15, line 60:

“transferred it to”

Page 29, line 23:

--transferred to--

Column 17, line 1:

“depends of the”

Page 32, line 2:

--depends on the--

Column 17, line 9:

“adjusted to pH to 4.5”

Page 32, line 9:

--adjusted to pH 4.5--

Column 17, line 31:

“exchange is carried out”

Page 33, line 1:

--exchange and carried out--

**Patent Reads:**

Column 19, line 26:

“was ravaged”

**Application Reads:**

Page 36, line 17:

--was lavaged--

**Patent Reads:**

Column 19, line 55:

“Paaavola”

**Application Should Read:**

Page 37, line 10:

--Paavola--

**Patent Reads:**Column 20, line 33:

“400 || L”

**Patent Reads:**Column 22, line 37:

“mutated in way that”

**Patent Reads:**Column 24, line 22:

“6569-4584”

**Application Reads:**Page 38, line 16:

--400 μL--

**Application Should Read:**Page 42, line 10:

--mutated in a way that--

**Application Reads:**Page 46, line 20:


--6569-6584--.

A true and correct copy of pages 36, 38, and 46 of the specification as filed which support Applicants' assertion of the errors on the part of the Patent Office accompanies this Certificate of Correction.

The fee of \$100.00 was paid at the time this Request was filed. The Commissioner is also authorized to charge any additional fees as required under 37 CFR 1.20(a) to Deposit Account No. 19-0065.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Copy of pages 36, 38, and 46 of the specification  
Certificate of Correction

(saline). The mice were sacrificed on at 4 hours after the CCL2 or CCL2-P8A final injection.

The assay for thioglycollate-induced peritoneal cell recruitment has been published (Mishell B, 1980). Briefly, thioglycollate medium was prepared by suspending 5 30 g of dehydrated thioglycollate medium (Becton Dickinson) in 1 liter of cold distilled water, then heated until boiling to dissolve the powder completely. The medium was then aliquoted into 100 ml bottles and autoclaved. After cooling, the medium was stored in the dark at room temperature for at least one month. Cellular recruitment was induced by intraperitoneal injection of mice in groups of 3 with 200  $\mu$ l of a 3% solution 10 of thioglycollate on Day 1, 30 minutes after CCL2\*-P8A administration. CCL2\* was administered daily thereafter for 3 days (Days 2, 3 and 4). Dexamethasone (Sigma) was used as a positive control and administered at 10 mg/kg intraperitoneally. The mice were sacrificed on Day 5.

Peritoneal lavages to assess cell recruitment in the previous assays were 15 performed as follows. Mice were sacrificed by asphyxiation with rising concentrations of CO<sub>2</sub> in a plexiglass box. Skin was cleaned with 70% ethanol. The outer layer of skin was removed, exposing the peritoneal membrane. The peritoneal cavity was lavaged 3 times with 5 ml ice cold PBS (phosphate buffered saline) and fluid was pooled in a 15 ml polystyrene Falcon tube (Becton Dickinson) on ice. Each lavage was accompanied 20 with a light massage of the peritoneal cavity. Lavage fluid was centrifuged at 425xg, the supernatant discarded and the resultant cell pellet was resuspended by gentle multiple pipetting in 1 ml PBS. 10  $\mu$ l cell suspension was stained with 90  $\mu$ l trypan blue and total cell counts were enumerated with a Neubauer haemocytometer by counting 4 areas each of 1 mm<sup>2</sup>. The mean of the 4 counts was taken, multiplied by the dilution factor of 25 10, and multiplied again by 10 to give the number of cells per  $\mu$ l, according to the

total volume of 200 µl, which were prepared by mixing 25 µl ovalbumin (2mg/ml), 250 µl aluminium hydroxide in 725 µl LPS-free 0.9% NaCl (saline) and precipitated 3-4 hours at 4°C. Fifteen days after sensitisation, mice were treated and challenged in groups of 6 mice with the intranasal administration of 15 µg ovalbumin in 50 µl saline, 5 under inhaled anaesthesia (Isoflurane) daily from day 15 to 19. CCL2-P8A (200 µl, 10 µg per intraperitoneal injection) was administered 30 minutes before each challenge. Peritoneal lavages to assess cell recruitment and cell counts were performed as described above in Example 2.

*EAE (Experimental Autoimmune Encephalomyelitis) model*

10 C57Bl/6 mice from Charles River Italy (the selected strain has documented susceptibility to EAE; Sahrbacher UC et al., 1998.) are immunized (day=0) by injecting s.c. in the left flank 0.2 mL of an emulsion composed of 200 µg MOG<sub>35-55</sub> peptide (Neosystem, Strasbourg, France) in Complete Freund's Adjuvant (CFA, Difco, Detroit, U.S.A.) containing 0.5 mg of *Mycobacterium tuberculosis*. Immediately after, they 15 receive an i.p. injection of 500 ng pertussis toxin (List Biological Lab., Campbell, CA, U.S.A.) dissolved in 400 µL of buffer (0.5 M NaCl, 0.017% Triton X-100, 0.015 M Tris, pH=7.5). On day 2, the animals are given a second i.p. injection of 500 ng pertussis toxin. On day 7, the mice receive a second dose of 200 µg of MOG<sub>35-55</sub> peptide in CFA injected s.c. in the right flank. Starting approximately from day 8-10, this procedure 20 results in a gradually progressing paralysis, arising from the tail and ascending up to the forelimbs. Starting from day 7 the animals are individually examined for the presence of paralysis by means of a clinical score as follows:

0 = no sign of disease

0.5 = partial tail paralysis

25 1 = tail paralysis

## REFERENCES

- Alexander JM et al., *Cell*, 111; 343-356, 2002.
- Baggiolini M et al., *Annu Rev Immunol*, 15: 675-705, 1997.
- Baggiolini M, *J Intern Med*, 250: 91-104, 2001.
- 5 Blyth DI et al., *Am J Respir Cell Mol Biol*, 14: 425-438, 1996.
- Brown A et al., *J Pept Sci* 2 :40-46, 1996.
- Cleland JL et al., *Curr Opin Biotechnol*, 12: 212-219, 2001.
- Coleman RA et al., *Drug Disc Today*, 6:1116-1126, 2001.
- Dougherty DA, *Curr Opin Chem Bio*, 4: 645-652, 2000.
- 10 Fernandez EJ and Lolis E, *Annu Rev Pharmacol Toxicol*, 42:469 -499, 2002.
- Garrigue JL et al., *Contact Dermatitis*, 30: 231-237, 1994.
- Godessart N and Kunkel SL, *Curr Opin Immunol*, 13: 670-675, 2001.
- Golebiowski A et al., *Curr Opin Drug Discov Devel*, 4: 428-434, 2001.
- Gong J and Clark-Lewis I, *J Exp Med* 181: 631-640, 1995.
- 15 Gosling J et al., *J Clin Invest*, 103: 773-778, 1999.
- Greenwald RB et al., *Adv Drug Deliv Rev*, 55: 217-50, 2003.
- Gu L et al., *Chem Immunol*, 72: 7-29, 1999.
- Gu L et al., *Nature*, 404: 407-411, 2000.
- Harris JM and Chess RB, *Nat Rev Drug Discov*, 2: 214-21, 2003.
- 20 Handel T et al., *Biochemistry*,35 : 6569-6584, 1996.
- Hemmerich S et al., *Biochemistry*, 38: 13013-13025, 1999.
- Hruby VJ and Balse PM, *Curr Med Chem*, 7:945-970, 2000.
- Izikson L et al., *Clin Immunol*, 103: 125-31 2002.
- Kim KS et al.,, *FEBS Lett*, 395:277-282, 1996.
- 25 Li AP, *Drug Disc Today*, 6: 357-366, 2001

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,740,833

Page 1 of 2

APPLICATION NO.: 10/573,625

DATED : June 22, 2010

INVENTORS : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2,

Line 13, "relate d to" should read --related to--.

Line 18, "even though has been" should read --even though it has been--.

Column 5,

Line 45, "results altered" should read --results are altered--.

Column 10,

Line 17, "derived form" should read --derived from--.

Column 13,

Lines 10-12, "fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl" should read --fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl--.

Column 15,

Line 60, "transferred it to" should read --transferred to--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,740,833

Page 2 of 2

APPLICATION NO.: 10/573,625

DATED : June 22, 2010

INVENTORS : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 17,

Line 1, "depends of the" should read --depends on the--.

Line 9, "adjusted to pH to 4.5" should read --adjusted to pH 4.5--.

Line 31, "exchange is carried out" should read --exchange and carried out--.

Column 19,

Line 26, "was ravaged" should read --was lavaged--.

Line 55, "Paaavola" should read --Paavola--.

Column 20,

Line 33, "400 †L" should read -- 400 µL--.

Column 22,

Line 37, "mutated in way that" should read --mutated in a way that--.

Column 24,

Line 22, "6569-4584" should read --6569-6584--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950